Trials & R&D · first seen 20h ago, updated 20h ago

Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing

1 outlet Alzheimer's drugs

Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3 program.

Summary from Fierce Biotech - Biotech.

Coverage 1 article · 1 outlet

Fierce Biotech - Biotech 20h ago
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing